title: NAT2 and CYP1A2 polymorphisms and lung cancer risk in relation to smoking status.
abstract: We investigated the associations between lung cancer and the gene polymorphisms of the drug metabolizing enzymes, containing cytochrome P450 1A1 (CYP1A1), cytochrome P450 1A2 (CYP1A2), glutathione S-transferase class mu (GSTM1), and N-acetyltransferase 2 (NAT2). The study involved 113 lung cancer patients and 121 non-cancer controls divided into never, light and heavy smokers according to pack-years of smoking in Japanese by using PCR-RFLP. For light smokers, the lung cancer risk of NAT2 intermediate-slow was significantly increased [the adjusted odds ratio (OR): 10.9, 95% confidence intervals (95%CI): 1.75-67.5, P-value: 0.010]. Moreover, never smokers having joint genotypes of NAT2 intermediate-slow and CYP1A2*1F A/A was also associated with increased the lung cancer risk (OR: 4.95, 95% CI: 1.19-20.6, P-value: 0.028). We suggested that light smokers with intermediate-slow NAT2 activity were at highest risk for lung cancer and the gene-gene interaction based on intermediate-slow NAT2 activity and high CYP1A2 activity would be increased a lung cancer risk among never smokers.
authors.affiliation: Kobe University Graduate School of Medicine, Tomogaoka, Sumaku, Kobe 654-0142, Japan.
authors.forename: Yasunori
authors.initials: Y
authors.lastname: Osawa
authors.forename: Kayo Kumar
authors.initials: KK
authors.lastname: Osawa
authors.forename: Aiko
authors.initials: A
authors.lastname: Miyaishi
authors.forename: Miho
authors.initials: M
authors.lastname: Higuchi
authors.forename: Akimitsu
authors.initials: A
authors.lastname: Tsutou
authors.forename: Sueo
authors.initials: S
authors.lastname: Matsumura
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Tabuchi
authors.forename: Noriaki
authors.initials: N
authors.lastname: Tsubota
authors.forename: Juro
authors.initials: J
authors.lastname: Takahashi
mesh_terms: D000230:Adenocarcinoma / Q000453:epidemiology / Q000235:genetics; D000368:Aged; D001191:Arylamine N-Acetyltransferase / Q000235:genetics*; D002294:Carcinoma, Squamous Cell / Q000453:epidemiology / Q000235:genetics; D016022:Case-Control Studies; D019388:Cytochrome P-450 CYP1A2 / Q000235:genetics*; D005260:Female; D005838:Genotype; D005982:Glutathione Transferase / Q000235:genetics; D006801:Humans; D007564:Japan; D008175:Lung Neoplasms / Q000453:epidemiology / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic / Q000235:genetics*; D012150:Polymorphism, Restriction Fragment Length; D012307:Risk Factors; D012907:Smoking / Q000009:adverse effects*; D011795:Surveys and Questionnaires; D013997:Time Factors
chemical_list: D019388:Cytochrome P-450 CYP1A2; D001191:Arylamine N-Acetyltransferase; C478900:NAT2 protein, human; D005982:Glutathione Transferase